On Monday, EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) was 3.60% up from the session before settling in for the closing price of $9.71. A 52-week range for EYPT has been $3.91 – $13.98.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 15.65%. When this article was written, the company’s average yearly earnings per share was at -31.20%. With a float of $59.79 million, this company’s outstanding shares have now reached $68.81 million.
Considering the fact that the conglomerate employs 165 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 93.29%, operating margin of -287.94%, and the pretax margin is -261.75%.
EyePoint Pharmaceuticals Inc (EYPT) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward EyePoint Pharmaceuticals Inc stocks. The insider ownership of EyePoint Pharmaceuticals Inc is 13.11%, while institutional ownership is 99.47%. The most recent insider transaction that took place on May 19 ’25, was worth 29,950. In this transaction Director of this company bought 5,000 shares at a rate of $5.99, taking the stock ownership to the 36,500 shares. Before that another transaction happened on May 16 ’25, when Company’s Director bought 5,000 for $5.81, making the entire transaction worth $29,050. This insider now owns 31,500 shares in total.
EyePoint Pharmaceuticals Inc (EYPT) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around -31.20% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -1.73% during the next five years compared to 15.65% growth over the previous five years of trading.
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) Trading Performance Indicators
You can see what EyePoint Pharmaceuticals Inc (EYPT) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 7.79. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 12.35.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.41, a number that is poised to hit -0.82 in the next quarter and is forecasted to reach -2.93 in one year’s time.
Technical Analysis of EyePoint Pharmaceuticals Inc (EYPT)
Compared to the last year’s volume of 0.81 million, its volume of 0.5 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 17.72%.
During the past 100 days, EyePoint Pharmaceuticals Inc’s (EYPT) raw stochastic average was set at 79.05%, which indicates a significant increase from 38.34% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.52 in the past 14 days, which was lower than the 0.57 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $9.21, while its 200-day Moving Average is $8.01.
